null

SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1

InChI Key: InChIKey=YMRFUSDFDQZOFK-STXQHDJLSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 454875   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
von Hippel-Lindau disease tumor suppressor (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2.19E+3	n/a	n/a	n/a	n/a	n/a	n/a
ARVINAS OPERATIONS, INC.; YALE UNIVERSITY US Patent					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				US Patent US10730870 (2020) BindingDB Entry DOI: 10.7270/Q2WD43MN
					More data for this Ligand-Target Pair
von Hippel-Lindau disease tumor suppressor (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	758	n/a	n/a	n/a	n/a	n/a	n/a
ARVINAS OPERATIONS, INC.; YALE UNIVERSITY US Patent					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				US Patent US10730870 (2020) BindingDB Entry DOI: 10.7270/Q2WD43MN
					More data for this Ligand-Target Pair
VHL complex (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1.09E+3	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				Citation and Details BindingDB Entry DOI: 10.7270/Q20K2DC4
					More data for this Ligand-Target Pair
VHL complex (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	2.19E+3	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				Citation and Details BindingDB Entry DOI: 10.7270/Q20K2DC4
					More data for this Ligand-Target Pair
VHL complex (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	758	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				Citation and Details BindingDB Entry DOI: 10.7270/Q20K2DC4
					More data for this Ligand-Target Pair
von Hippel-Lindau disease tumor suppressor (Homo sapiens (Human))	BDBM454875 (US10730870, Example 38 | US11512083, Example 38) Show SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](C2CCCC2)N2Cc3ccccc3C2=O)cc1 |r| Show InChI InChI=1S/C31H34N4O4S/c1-19-28(40-18-33-19)22-12-10-20(11-13-22)15-32-29(37)26-14-24(36)17-34(26)31(39)27(21-6-2-3-7-21)35-16-23-8-4-5-9-25(23)30(35)38/h4-5,8-13,18,21,24,26-27,36H,2-3,6-7,14-17H2,1H3,(H,32,37)/t24-,26+,27+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	KEGG PC cid PC sid UniChem	US Patent	n/a	n/a	1.09E+3	n/a	n/a	n/a	n/a	n/a	n/a
ARVINAS OPERATIONS, INC.; YALE UNIVERSITY US Patent					Assay Description Ability of VHL ligands to compete for the HIF 1 a binding site on VCB was determined through a fluorescence polarization competition assay as describ...				US Patent US10730870 (2020) BindingDB Entry DOI: 10.7270/Q2WD43MN
					More data for this Ligand-Target Pair